Gerresheimer AG (GRRMF) Stock Competitors & Peer Comparison
See (GRRMF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRRMF | $32.10 | -0.31% | 1.1B | 40.63 | $0.79 | +0.14% |
| SRTOY | $20.59 | +0.15% | 196.5B | 63.11 | $0.32 | +0.41% |
| ESLOF | $201.24 | -0.38% | 94.4B | 35.20 | $5.79 | +2.33% |
| ESLOY | $99.28 | -2.34% | 92.5B | 34.72 | $2.90 | +2.34% |
| SOAGY | $56.60 | -0.69% | 82.9B | 103.13 | $0.55 | +0.30% |
| HOCPY | $166.24 | -2.38% | 55.6B | 35.67 | $4.66 | +1.04% |
| HOCPF | $160.69 | -3.30% | 53.8B | 34.56 | $4.65 | +1.15% |
| MECNY | $88.63 | +0.00% | 26.9B | N/A | N/A | N/A |
| TRUMY | $14.08 | -6.38% | 21.6B | 25.21 | $0.58 | +1.18% |
| TRUMF | $13.60 | -10.08% | 20.1B | 23.45 | $0.58 | +1.44% |
Stock Comparison
GRRMF vs SRTOY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SRTOY has a market cap of 196.5B. Regarding current trading prices, GRRMF is priced at $32.10, while SRTOY trades at $20.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SRTOY's P/E ratio is 63.11. In terms of profitability, GRRMF's ROE is +0.02%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SRTOY's competition here
GRRMF vs ESLOF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ESLOF has a market cap of 94.4B. Regarding current trading prices, GRRMF is priced at $32.10, while ESLOF trades at $201.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ESLOF's P/E ratio is 35.20. In terms of profitability, GRRMF's ROE is +0.02%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to ESLOF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ESLOF's competition here
GRRMF vs ESLOY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ESLOY has a market cap of 92.5B. Regarding current trading prices, GRRMF is priced at $32.10, while ESLOY trades at $99.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ESLOY's P/E ratio is 34.72. In terms of profitability, GRRMF's ROE is +0.02%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to ESLOY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ESLOY's competition here
GRRMF vs SOAGY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SOAGY has a market cap of 82.9B. Regarding current trading prices, GRRMF is priced at $32.10, while SOAGY trades at $56.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SOAGY's P/E ratio is 103.13. In terms of profitability, GRRMF's ROE is +0.02%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SOAGY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SOAGY's competition here
GRRMF vs HOCPY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, HOCPY has a market cap of 55.6B. Regarding current trading prices, GRRMF is priced at $32.10, while HOCPY trades at $166.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas HOCPY's P/E ratio is 35.67. In terms of profitability, GRRMF's ROE is +0.02%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, GRRMF is less volatile compared to HOCPY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check HOCPY's competition here
GRRMF vs HOCPF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, HOCPF has a market cap of 53.8B. Regarding current trading prices, GRRMF is priced at $32.10, while HOCPF trades at $160.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas HOCPF's P/E ratio is 34.56. In terms of profitability, GRRMF's ROE is +0.02%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, GRRMF is more volatile compared to HOCPF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check HOCPF's competition here
GRRMF vs MECNY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, MECNY has a market cap of 26.9B. Regarding current trading prices, GRRMF is priced at $32.10, while MECNY trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas MECNY's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, GRRMF is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check MECNY's competition here
GRRMF vs TRUMY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TRUMY has a market cap of 21.6B. Regarding current trading prices, GRRMF is priced at $32.10, while TRUMY trades at $14.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TRUMY's P/E ratio is 25.21. In terms of profitability, GRRMF's ROE is +0.02%, compared to TRUMY's ROE of +0.09%. Regarding short-term risk, GRRMF is less volatile compared to TRUMY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TRUMY's competition here
GRRMF vs TRUMF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TRUMF has a market cap of 20.1B. Regarding current trading prices, GRRMF is priced at $32.10, while TRUMF trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TRUMF's P/E ratio is 23.45. In terms of profitability, GRRMF's ROE is +0.02%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, GRRMF is more volatile compared to TRUMF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check TRUMF's competition here
GRRMF vs SDMHF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SDMHF has a market cap of 19.4B. Regarding current trading prices, GRRMF is priced at $32.10, while SDMHF trades at $205.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SDMHF's P/E ratio is 62.02. In terms of profitability, GRRMF's ROE is +0.02%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, GRRMF is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SDMHF's competition here
GRRMF vs SAUHY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SAUHY has a market cap of 19.1B. Regarding current trading prices, GRRMF is priced at $32.10, while SAUHY trades at $11.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SAUHY's P/E ratio is 42.79. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, GRRMF is less volatile compared to SAUHY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SAUHY's competition here
GRRMF vs SAUHF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SAUHF has a market cap of 17.4B. Regarding current trading prices, GRRMF is priced at $32.10, while SAUHF trades at $123.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SAUHF's P/E ratio is 38.52. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, GRRMF is more volatile compared to SAUHF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SAUHF's competition here
GRRMF vs SUVPF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SUVPF has a market cap of 16.2B. Regarding current trading prices, GRRMF is priced at $32.10, while SUVPF trades at $276.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SUVPF's P/E ratio is 85.37. In terms of profitability, GRRMF's ROE is +0.02%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SUVPF's competition here
GRRMF vs SARTF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SARTF has a market cap of 15.7B. Regarding current trading prices, GRRMF is priced at $32.10, while SARTF trades at $227.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SARTF's P/E ratio is 83.46. In terms of profitability, GRRMF's ROE is +0.02%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, GRRMF is more volatile compared to SARTF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SARTF's competition here
GRRMF vs SSSGY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SSSGY has a market cap of 14.4B. Regarding current trading prices, GRRMF is priced at $32.10, while SSSGY trades at $44.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SSSGY's P/E ratio is 75.82. In terms of profitability, GRRMF's ROE is +0.02%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to SSSGY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SSSGY's competition here
GRRMF vs FSPKF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, FSPKF has a market cap of 12.1B. Regarding current trading prices, GRRMF is priced at $32.10, while FSPKF trades at $20.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas FSPKF's P/E ratio is 46.70. In terms of profitability, GRRMF's ROE is +0.02%, compared to FSPKF's ROE of +0.23%. Regarding short-term risk, GRRMF is more volatile compared to FSPKF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check FSPKF's competition here
GRRMF vs AHICF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, AHICF has a market cap of 6B. Regarding current trading prices, GRRMF is priced at $32.10, while AHICF trades at $21.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas AHICF's P/E ratio is 53.81. In terms of profitability, GRRMF's ROE is +0.02%, compared to AHICF's ROE of +0.20%. Regarding short-term risk, GRRMF is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check AHICF's competition here
GRRMF vs SSMXY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SSMXY has a market cap of 5.7B. Regarding current trading prices, GRRMF is priced at $32.10, while SSMXY trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SSMXY's P/E ratio is 25.28. In terms of profitability, GRRMF's ROE is +0.02%, compared to SSMXY's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to SSMXY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SSMXY's competition here
GRRMF vs CNVVF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CNVVF has a market cap of 5.3B. Regarding current trading prices, GRRMF is priced at $32.10, while CNVVF trades at $2.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CNVVF's P/E ratio is 30.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, GRRMF is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CNVVF's competition here
GRRMF vs CNVVY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CNVVY has a market cap of 5.1B. Regarding current trading prices, GRRMF is priced at $32.10, while CNVVY trades at $10.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CNVVY's P/E ratio is 30.97. In terms of profitability, GRRMF's ROE is +0.02%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, GRRMF is less volatile compared to CNVVY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CNVVY's competition here
GRRMF vs SSMXF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SSMXF has a market cap of 5.1B. Regarding current trading prices, GRRMF is priced at $32.10, while SSMXF trades at $8.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SSMXF's P/E ratio is 22.92. In terms of profitability, GRRMF's ROE is +0.02%, compared to SSMXF's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to SSMXF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SSMXF's competition here
GRRMF vs FLMNF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, FLMNF has a market cap of 4.4B. Regarding current trading prices, GRRMF is priced at $32.10, while FLMNF trades at $50.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas FLMNF's P/E ratio is 18.61. In terms of profitability, GRRMF's ROE is +0.02%, compared to FLMNF's ROE of +0.22%. Regarding short-term risk, GRRMF is less volatile compared to FLMNF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check FLMNF's competition here
GRRMF vs FLMNY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, FLMNY has a market cap of 4.3B. Regarding current trading prices, GRRMF is priced at $32.10, while FLMNY trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas FLMNY's P/E ratio is 17.77. In terms of profitability, GRRMF's ROE is +0.02%, compared to FLMNY's ROE of +0.21%. Regarding short-term risk, GRRMF is less volatile compared to FLMNY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check FLMNY's competition here
GRRMF vs ANSLF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ANSLF has a market cap of 3.2B. Regarding current trading prices, GRRMF is priced at $32.10, while ANSLF trades at $22.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, GRRMF's ROE is +0.02%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, GRRMF is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check ANSLF's competition here
GRRMF vs ANSLY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ANSLY has a market cap of 2.8B. Regarding current trading prices, GRRMF is priced at $32.10, while ANSLY trades at $74.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ANSLY's P/E ratio is 21.17. In terms of profitability, GRRMF's ROE is +0.02%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to ANSLY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ANSLY's competition here
GRRMF vs CZMWF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CZMWF has a market cap of 2.8B. Regarding current trading prices, GRRMF is priced at $32.10, while CZMWF trades at $30.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CZMWF's P/E ratio is 17.11. In terms of profitability, GRRMF's ROE is +0.02%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, GRRMF is more volatile compared to CZMWF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check CZMWF's competition here
GRRMF vs CZMWY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CZMWY has a market cap of 2.7B. Regarding current trading prices, GRRMF is priced at $32.10, while CZMWY trades at $30.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CZMWY's P/E ratio is 16.26. In terms of profitability, GRRMF's ROE is +0.02%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, GRRMF is less volatile compared to CZMWY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CZMWY's competition here
GRRMF vs EKTAF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, EKTAF has a market cap of 2.4B. Regarding current trading prices, GRRMF is priced at $32.10, while EKTAF trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas EKTAF's P/E ratio is -43.33. In terms of profitability, GRRMF's ROE is +0.02%, compared to EKTAF's ROE of -0.06%. Regarding short-term risk, GRRMF is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check EKTAF's competition here
GRRMF vs SHWGF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SHWGF has a market cap of 2.2B. Regarding current trading prices, GRRMF is priced at $32.10, while SHWGF trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SHWGF's P/E ratio is 10.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to SHWGF's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to SHWGF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SHWGF's competition here
GRRMF vs EKTAY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, EKTAY has a market cap of 2.2B. Regarding current trading prices, GRRMF is priced at $32.10, while EKTAY trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas EKTAY's P/E ratio is -37.53. In terms of profitability, GRRMF's ROE is +0.02%, compared to EKTAY's ROE of -0.06%. Regarding short-term risk, GRRMF is less volatile compared to EKTAY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check EKTAY's competition here
GRRMF vs SHWGY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SHWGY has a market cap of 2B. Regarding current trading prices, GRRMF is priced at $32.10, while SHWGY trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SHWGY's P/E ratio is 8.26. In terms of profitability, GRRMF's ROE is +0.02%, compared to SHWGY's ROE of +0.07%. Regarding short-term risk, GRRMF is less volatile compared to SHWGY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SHWGY's competition here
GRRMF vs ADDLF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ADDLF has a market cap of 1.8B. Regarding current trading prices, GRRMF is priced at $32.10, while ADDLF trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ADDLF's P/E ratio is 23.16. In terms of profitability, GRRMF's ROE is +0.02%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, GRRMF is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ADDLF's competition here
GRRMF vs TGLVY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TGLVY has a market cap of 1.7B. Regarding current trading prices, GRRMF is priced at $32.10, while TGLVY trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TGLVY's P/E ratio is 42.57. In terms of profitability, GRRMF's ROE is +0.02%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, GRRMF is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TGLVY's competition here
GRRMF vs NPRRF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, GRRMF is priced at $32.10, while NPRRF trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas NPRRF's P/E ratio is 21.07. In terms of profitability, GRRMF's ROE is +0.02%, compared to NPRRF's ROE of N/A. Regarding short-term risk, GRRMF is less volatile compared to NPRRF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check NPRRF's competition here
GRRMF vs BITGF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, GRRMF is priced at $32.10, while BITGF trades at $15.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas BITGF's P/E ratio is 45.50. In terms of profitability, GRRMF's ROE is +0.02%, compared to BITGF's ROE of +0.04%. Regarding short-term risk, GRRMF is less volatile compared to BITGF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check BITGF's competition here
GRRMF vs PBHDF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, GRRMF is priced at $32.10, while PBHDF trades at $19.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, GRRMF's ROE is +0.02%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, GRRMF is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check PBHDF's competition here
GRRMF vs SAFLY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SAFLY has a market cap of 1.1B. Regarding current trading prices, GRRMF is priced at $32.10, while SAFLY trades at $3.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SAFLY's P/E ratio is 13.93. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAFLY's ROE of +0.12%. Regarding short-term risk, GRRMF is less volatile compared to SAFLY. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SAFLY's competition here
GRRMF vs JNDOF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, JNDOF has a market cap of 1.1B. Regarding current trading prices, GRRMF is priced at $32.10, while JNDOF trades at $47.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas JNDOF's P/E ratio is 98.38. In terms of profitability, GRRMF's ROE is +0.02%, compared to JNDOF's ROE of +0.23%. Regarding short-term risk, GRRMF is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check JNDOF's competition here
GRRMF vs HGYMF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, HGYMF has a market cap of 937.2M. Regarding current trading prices, GRRMF is priced at $32.10, while HGYMF trades at $34.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas HGYMF's P/E ratio is 228.79. In terms of profitability, GRRMF's ROE is +0.02%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, GRRMF is less volatile compared to HGYMF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check HGYMF's competition here
GRRMF vs TDVXF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TDVXF has a market cap of 920.7M. Regarding current trading prices, GRRMF is priced at $32.10, while TDVXF trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TDVXF's P/E ratio is 48.46. In terms of profitability, GRRMF's ROE is +0.02%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, GRRMF is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TDVXF's competition here
GRRMF vs SAFLF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SAFLF has a market cap of 906.6M. Regarding current trading prices, GRRMF is priced at $32.10, while SAFLF trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SAFLF's P/E ratio is 16.50. In terms of profitability, GRRMF's ROE is +0.02%, compared to SAFLF's ROE of +0.12%. Regarding short-term risk, GRRMF is more volatile compared to SAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SAFLF's competition here
GRRMF vs KSRBF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, KSRBF has a market cap of 839.6M. Regarding current trading prices, GRRMF is priced at $32.10, while KSRBF trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, GRRMF's ROE is +0.02%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, GRRMF is more volatile compared to KSRBF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check KSRBF's competition here
GRRMF vs NNCSF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, NNCSF has a market cap of 747M. Regarding current trading prices, GRRMF is priced at $32.10, while NNCSF trades at $2.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas NNCSF's P/E ratio is 50.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, GRRMF is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check NNCSF's competition here
GRRMF vs SPMXF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, GRRMF is priced at $32.10, while SPMXF trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to SPMXF's ROE of -0.08%. Regarding short-term risk, GRRMF is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check SPMXF's competition here
GRRMF vs CLHLF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CLHLF has a market cap of 455.6M. Regarding current trading prices, GRRMF is priced at $32.10, while CLHLF trades at $61.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CLHLF's P/E ratio is 34.82. In terms of profitability, GRRMF's ROE is +0.02%, compared to CLHLF's ROE of +0.16%. Regarding short-term risk, GRRMF is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check CLHLF's competition here
GRRMF vs TSNLF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TSNLF has a market cap of 287.9M. Regarding current trading prices, GRRMF is priced at $32.10, while TSNLF trades at $5.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TSNLF's P/E ratio is 27.27. In terms of profitability, GRRMF's ROE is +0.02%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, GRRMF is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TSNLF's competition here
GRRMF vs OPSSF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, GRRMF is priced at $32.10, while OPSSF trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, GRRMF's ROE is +0.02%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, GRRMF is less volatile compared to OPSSF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check OPSSF's competition here
GRRMF vs EEOIF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, GRRMF is priced at $32.10, while EEOIF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, GRRMF's ROE is +0.02%, compared to EEOIF's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check EEOIF's competition here
GRRMF vs OTCFF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, OTCFF has a market cap of 21M. Regarding current trading prices, GRRMF is priced at $32.10, while OTCFF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas OTCFF's P/E ratio is -13.11. In terms of profitability, GRRMF's ROE is +0.02%, compared to OTCFF's ROE of +1.88%. Regarding short-term risk, GRRMF is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check OTCFF's competition here
GRRMF vs UEEC Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, UEEC has a market cap of 13.7M. Regarding current trading prices, GRRMF is priced at $32.10, while UEEC trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas UEEC's P/E ratio is -5.27. In terms of profitability, GRRMF's ROE is +0.02%, compared to UEEC's ROE of +0.40%. Regarding short-term risk, GRRMF is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check UEEC's competition here
GRRMF vs BLMHF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, GRRMF is priced at $32.10, while BLMHF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, GRRMF's ROE is +0.02%, compared to BLMHF's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check BLMHF's competition here
GRRMF vs PXMVF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, GRRMF is priced at $32.10, while PXMVF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, GRRMF's ROE is +0.02%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, GRRMF is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check PXMVF's competition here
GRRMF vs CBSC Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CBSC has a market cap of 4.4M. Regarding current trading prices, GRRMF is priced at $32.10, while CBSC trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CBSC's P/E ratio is -3.94. In terms of profitability, GRRMF's ROE is +0.02%, compared to CBSC's ROE of +0.58%. Regarding short-term risk, GRRMF is less volatile compared to CBSC. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check CBSC's competition here
GRRMF vs MCDA Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, GRRMF is priced at $32.10, while MCDA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas MCDA's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MCDA's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check MCDA's competition here
GRRMF vs GVDI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, GRRMF is priced at $32.10, while GVDI trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas GVDI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, GRRMF is less volatile compared to GVDI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check GVDI's competition here
GRRMF vs TUTH Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TUTH has a market cap of 4.2M. Regarding current trading prices, GRRMF is priced at $32.10, while TUTH trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TUTH's P/E ratio is -1.67. In terms of profitability, GRRMF's ROE is +0.02%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, GRRMF is less volatile compared to TUTH. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TUTH's competition here
GRRMF vs RSCF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, RSCF has a market cap of 4.1M. Regarding current trading prices, GRRMF is priced at $32.10, while RSCF trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas RSCF's P/E ratio is -4.75. In terms of profitability, GRRMF's ROE is +0.02%, compared to RSCF's ROE of +0.10%. Regarding short-term risk, GRRMF is less volatile compared to RSCF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check RSCF's competition here
GRRMF vs NSTGQ Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, GRRMF is priced at $32.10, while NSTGQ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, GRRMF is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check NSTGQ's competition here
GRRMF vs YBGJ Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, YBGJ has a market cap of 1M. Regarding current trading prices, GRRMF is priced at $32.10, while YBGJ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas YBGJ's P/E ratio is -0.84. In terms of profitability, GRRMF's ROE is +0.02%, compared to YBGJ's ROE of +0.37%. Regarding short-term risk, GRRMF is more volatile compared to YBGJ. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check YBGJ's competition here
GRRMF vs OJSY Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, GRRMF is priced at $32.10, while OJSY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas OJSY's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to OJSY's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check OJSY's competition here
GRRMF vs PDMI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, GRRMF is priced at $32.10, while PDMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas PDMI's P/E ratio is -0.01. In terms of profitability, GRRMF's ROE is +0.02%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, GRRMF is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check PDMI's competition here
GRRMF vs WHSI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, GRRMF is priced at $32.10, while WHSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas WHSI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, GRRMF is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check WHSI's competition here
GRRMF vs BLFE Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, GRRMF is priced at $32.10, while BLFE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas BLFE's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, GRRMF is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check BLFE's competition here
GRRMF vs ECIA Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ECIA has a market cap of 124.5K. Regarding current trading prices, GRRMF is priced at $32.10, while ECIA trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ECIA's P/E ratio is -0.33. In terms of profitability, GRRMF's ROE is +0.02%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, GRRMF is less volatile compared to ECIA. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ECIA's competition here
GRRMF vs QTXB Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, GRRMF is priced at $32.10, while QTXB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas QTXB's P/E ratio is -0.05. In terms of profitability, GRRMF's ROE is +0.02%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, GRRMF is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check QTXB's competition here
GRRMF vs LANZ Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, LANZ has a market cap of 110.4K. Regarding current trading prices, GRRMF is priced at $32.10, while LANZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas LANZ's P/E ratio is 4.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, GRRMF is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check LANZ's competition here
GRRMF vs CEOS Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, CEOS has a market cap of 90.4K. Regarding current trading prices, GRRMF is priced at $32.10, while CEOS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas CEOS's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to CEOS's ROE of +7.33%. Regarding short-term risk, GRRMF is more volatile compared to CEOS. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check CEOS's competition here
GRRMF vs IMTH Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, IMTH has a market cap of 71.8K. Regarding current trading prices, GRRMF is priced at $32.10, while IMTH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas IMTH's P/E ratio is -0.02. In terms of profitability, GRRMF's ROE is +0.02%, compared to IMTH's ROE of -0.60%. Regarding short-term risk, GRRMF is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check IMTH's competition here
GRRMF vs GMVDF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, GRRMF is priced at $32.10, while GMVDF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas GMVDF's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, GRRMF is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check GMVDF's competition here
GRRMF vs REMI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, GRRMF is priced at $32.10, while REMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas REMI's P/E ratio is -0.07. In terms of profitability, GRRMF's ROE is +0.02%, compared to REMI's ROE of -0.11%. Regarding short-term risk, GRRMF is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check REMI's competition here
GRRMF vs SDCCQ Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, GRRMF is priced at $32.10, while SDCCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, GRRMF is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SDCCQ's competition here
GRRMF vs MDIT Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, GRRMF is priced at $32.10, while MDIT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas MDIT's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, GRRMF is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check MDIT's competition here
GRRMF vs ASFX Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ASFX has a market cap of 5.3K. Regarding current trading prices, GRRMF is priced at $32.10, while ASFX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ASFX's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, GRRMF is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ASFX's competition here
GRRMF vs DGEN Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, GRRMF is priced at $32.10, while DGEN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas DGEN's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, GRRMF is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check DGEN's competition here
GRRMF vs SVSO Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, GRRMF is priced at $32.10, while SVSO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SVSO's P/E ratio is -0.01. In terms of profitability, GRRMF's ROE is +0.02%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, GRRMF is more volatile compared to SVSO. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SVSO's competition here
GRRMF vs LFPI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, GRRMF is priced at $32.10, while LFPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas LFPI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, GRRMF is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check LFPI's competition here
GRRMF vs SEYE Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, GRRMF is priced at $32.10, while SEYE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SEYE's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to SEYE's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SEYE's competition here
GRRMF vs BGMD Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, GRRMF is priced at $32.10, while BGMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas BGMD's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, GRRMF is more volatile compared to BGMD. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check BGMD's competition here
GRRMF vs ADLI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, GRRMF is priced at $32.10, while ADLI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas ADLI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, GRRMF is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check ADLI's competition here
GRRMF vs VSMD Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, GRRMF is priced at $32.10, while VSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas VSMD's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, GRRMF is more volatile compared to VSMD. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check VSMD's competition here
GRRMF vs TEVNF Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, GRRMF is priced at $32.10, while TEVNF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas TEVNF's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, GRRMF is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check TEVNF's competition here
GRRMF vs INND Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, INND has a market cap of 505. Regarding current trading prices, GRRMF is priced at $32.10, while INND trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas INND's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to INND's ROE of -0.01%. Regarding short-term risk, GRRMF is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for GRRMF.Check INND's competition here
GRRMF vs MICRD Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, GRRMF is priced at $32.10, while MICRD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas MICRD's P/E ratio is -0.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, GRRMF is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check MICRD's competition here
GRRMF vs HRAL Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, HRAL has a market cap of 297. Regarding current trading prices, GRRMF is priced at $32.10, while HRAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas HRAL's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to HRAL's ROE of +0.21%. Regarding short-term risk, GRRMF is more volatile compared to HRAL. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check HRAL's competition here
GRRMF vs RGBOQ Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, GRRMF is priced at $32.10, while RGBOQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check RGBOQ's competition here
GRRMF vs SECI Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, SECI has a market cap of 31. Regarding current trading prices, GRRMF is priced at $32.10, while SECI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas SECI's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to SECI's ROE of -0.00%. Regarding short-term risk, GRRMF is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check SECI's competition here
GRRMF vs VTEQ Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, GRRMF is priced at $32.10, while VTEQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, GRRMF's ROE is +0.02%, compared to VTEQ's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check VTEQ's competition here
GRRMF vs MEDVD Comparison June 2026
GRRMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRRMF stands at 1.1B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, GRRMF is priced at $32.10, while MEDVD trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRRMF currently has a P/E ratio of 40.63, whereas MEDVD's P/E ratio is N/A. In terms of profitability, GRRMF's ROE is +0.02%, compared to MEDVD's ROE of N/A. Regarding short-term risk, GRRMF is more volatile compared to MEDVD. This indicates potentially higher risk in terms of short-term price fluctuations for GRRMF.Check MEDVD's competition here